Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Braess

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
British Journal of Haematology|August 10, 2000
The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activityJ Braess, S Voss, G Jahns-Streubel, et al.
The British Journal of Dermatology|December 3, 1999
Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigusK Reich, U Brinck, M Letschert, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 12, 1998
Treatment of relapsing thrombotic thrombocytopenic purpura with cyclophosphamide pulse therapyF Strutz, U Wieneke, J Braess, et al.
Leukemia|March 10, 2001
Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSFG Jahns-Streubel, J Braess, C Schoch, et al.
Leukemia|January 22, 1998
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curveE Schleyer, S Kühn, H Rührs, et al.
Annals of Hematology|October 1, 1996
Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantroneJ Braess, W Kern, M Unterhalt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 4, 2001
Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancerW Kern, B Beckert, N Lang, et al.
British Journal of Haematology|July 10, 2001
Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemiaJ Braess, G Jahns-Streubel, C Schoch, et al.
Leukemia|October 10, 1998
Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. German AML Cooperative GroupW Kern, J Braess, A Grote-Metke, et al.
Critical Reviews in Oncology/Hematology|October 7, 2005
Towards a pathogenesis-oriented therapy of acute myeloid leukemiaW Hiddemann, K Spiekermann, C Buske, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
British Journal of Haematology|August 10, 2000
The pharmacodynamic basis for the increased antileukaemic efficacy of cytosine arabinoside-based treatment regimens in acute myeloid leukaemia with a high proliferative activityJ Braess, S Voss, G Jahns-Streubel, et al.
The British Journal of Dermatology|December 3, 1999
Graft-versus-host disease-like immunophenotype and apoptotic keratinocyte death in paraneoplastic pemphigusK Reich, U Brinck, M Letschert, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|June 12, 1998
Treatment of relapsing thrombotic thrombocytopenic purpura with cyclophosphamide pulse therapyF Strutz, U Wieneke, J Braess, et al.
Leukemia|March 10, 2001
Cytogenetic subgroups in acute myeloid leukemia differ in proliferative activity and response to GM-CSFG Jahns-Streubel, J Braess, C Schoch, et al.
Leukemia|January 22, 1998
Oral idarubicin pharmacokinetics--correlation of trough level with idarubicin area under curveE Schleyer, S Kühn, H Rührs, et al.
Annals of Hematology|October 1, 1996
Response to cytarabine ocfosfate (YNK01) in a patient with chronic lymphocytic leukemia refractory to treatment with chlorambucil/prednisone, fludarabine, and prednimustine/mitoxantroneJ Braess, W Kern, M Unterhalt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 4, 2001
Phase I and pharmacokinetic study of hepatic arterial infusion with oxaliplatin in combination with folinic acid and 5-fluorouracil in patients with hepatic metastases from colorectal cancerW Kern, B Beckert, N Lang, et al.
British Journal of Haematology|July 10, 2001
Proliferative activity of leukaemic blasts and cytosine arabinoside pharmacodynamics are associated with cytogenetically defined prognostic subgroups in acute myeloid leukaemiaJ Braess, G Jahns-Streubel, C Schoch, et al.
Leukemia|October 10, 1998
Combination of aclarubicin and etoposide for the treatment of advanced acute myeloid leukemia: results of a prospective multicenter phase II trial. German AML Cooperative GroupW Kern, J Braess, A Grote-Metke, et al.
Critical Reviews in Oncology/Hematology|October 7, 2005
Towards a pathogenesis-oriented therapy of acute myeloid leukemiaW Hiddemann, K Spiekermann, C Buske, et al.
Pageof 6